SYRS News and Press, Syros Pharmaceuticals Inc. From 02/05/24

2024-02-05 03:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-25 11:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-14 03:44:11 ET Summary Syros Pharmaceuticals is a cancer-focused biotech working on therapies for blood cancer, with a main drug in development. The company's main program is tamibarotene, targeting specific myeloid cancers with high RARA gene expression. Syros has enc...

-- On-Track to Complete Enrollment of 190 patients for Primary Analysis in SELECT-MDS-1 Phase 3 Trial in 1Q 2024; Pivotal CR Data Expected by Mid-4Q 2024 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in 2024; Initial Data Demonstrated 100% CR/CRi Rate and Favorable Tolera...

2023-12-27 02:04:59 ET More on Syros Pharmaceuticals Syros prices capital raise of $45.0 million via securities offering Syros jumps after Phase 2 data for leukemia therapy Seeking Alpha’s Quant Rating on Syros Pharmaceuticals For further details see: ...

2023-12-27 02:04:59 ET More on Syros Pharmaceuticals Syros prices capital raise of $45.0 million via securities offering Syros jumps after Phase 2 data for leukemia therapy Seeking Alpha’s Quant Rating on Syros Pharmaceuticals For further details see: ...

2023-12-19 07:49:27 ET More on Syros Pharmaceuticals Syros jumps after Phase 2 data for leukemia therapy Syros Pharmaceuticals GAAP EPS of -$1.43 misses by $0.29, revenue of $3.76M misses by $0.18M Seeking Alpha’s Quant Rating on Syros Pharmaceuticals ...

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per...

2023-12-06 17:29:59 ET DENVER, Colo., Dec. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or traded higher-than-usual volume; Sera Prognostics Inc (NASDAQ: SERA), MicroAlgo Inc (NASDAQ: MLGO), Syros Pharmaceuticals Inc (NASDAQ: SYRS), Altimmune Inc (N...

2023-12-06 13:46:53 ET Syros Pharmaceuticals ( NASDAQ: SYRS ) added ~41% on Wednesday after the Massachusetts area biotech disclosed early data from a Phase 2 trial evaluating its oral leukemia drug, tamibarotene, as a combination therapy. Based on data from 19 pat...